Harmony Biosciences Holdings (HRMY) FCF Margin (2020 - 2026)
Harmony Biosciences Holdings (HRMY) reported FCF Margin of 12.89% for Q1 2026, down 544.0% on a YoY basis from 2.9% in Q1 2025, and down 75.07% sequentially from 51.7% in Q4 2025.
Harmony Biosciences Holdings (HRMY) FCF Margin (2020 - 2026) Analysis & Trends
Harmony Biosciences Holdings (HRMY) has 7 years of FCF Margin data on file, last reported at 12.89% in Q1 2026.
- For the quarter ending Q1 2026, FCF Margin fell 544.0% year-over-year to 12.89%; the trailing twelve-month figure through Mar 2026 stood at 38.01% (up 829.0% YoY), and the FY2025 full-year result was 40.06%, up 946.0% from the prior year.
- FCF Margin declined to 12.89% in Q1 2026, from 51.7% in the prior quarter.
- In the past five years, FCF Margin ranged from a high of 51.7% in Q4 2025 to a low of 12.89% in Q1 2026.
- A 5-year average of 33.45% and a median of 35.73% in 2023 frame the typical range for FCF Margin.
- Across the five-year window, FCF Margin tumbled 2036 bps in 2022 and surged 2467 bps in 2023, its largest moves.
- Tracing HRMY's FCF Margin over 5 years: stood at 20.79% in 2022, then soared by 119 bps to 45.46% in 2023, then dropped by 18 bps to 37.29% in 2024, then jumped by 39 bps to 51.7% in 2025, then plunged by 75 bps to 12.89% in 2026.
- Business Quant data shows HRMY's FCF Margin at 12.89% in Q1 2026, 51.7% in Q4 2025, and 45.38% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.45% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 43.35% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.53% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Harmony Biosciences Holdings | 2.07 Bn | 1.55 Bn | 170.88 Mn | 12.89% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12.89% |
| Dec 31, 2025 | 51.70% |
| Sep 30, 2025 | 45.38% |
| Jun 30, 2025 | 39.56% |
| Mar 31, 2025 | 18.33% |
| Dec 31, 2024 | 37.29% |
| Sep 30, 2024 | 37.89% |
| Jun 30, 2024 | 24.29% |
| Mar 31, 2024 | 20.14% |
| Dec 31, 2023 | 45.46% |
| Sep 30, 2023 | 39.37% |
| Jun 30, 2023 | 27.61% |
| Mar 31, 2023 | 35.73% |
| Dec 31, 2022 | 20.79% |
| Sep 30, 2022 | 47.03% |
| Jun 30, 2022 | 31.48% |
| Mar 31, 2022 | 33.77% |
| Dec 31, 2021 | 41.15% |
| Sep 30, 2021 | 37.57% |
| Jun 30, 2021 | 24.21% |